



Trogarzo® Phase III Data Analysis Presented at HIV Drug Therapy Glasgow 2018: Patients not achieving primary endpoint at day 7 experienced clinical benefit by end of study

October 30, 2018

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that data from the phase III clinical trial of Trogarzo® (ibalizumab-uiyk) injection show that patients who did not achieve the primary endpoint of ≥ 0.5 log₁₀ viral load reduction seven days after receiving a loading dose of Trogarzo®, eventually did experience clinical benefits during the study.